Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...